Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730871 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
A Phase 4 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 173
- Enrollment target
NCT02730871: Clinical Trial Phase 4 study, sponsored by Alcon Research.
NCT02730871 is a Phase 4 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 173 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730871, a Phase 4 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 173 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
Primary Outcome
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry. Diurnal IOP change was defined as the average of the two changes from baseline (timepoints 9 AM, 11 AM). A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) was used for the analyses.
Interventions
- DRUG Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
- DRUG Brinzolamide/brimonidine vehicle
- DRUG Travoprost 0.004%/timolol 0.5% solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2016-06-24 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 4 |
Why NCT02730871 stopped before completion
NCT02730871 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension is the first listed.
NCT02730871 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02730871 about?
NCT02730871 is a clinical study titled "Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®". The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT02730871?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2016-06-24. Estimated completion is 2018-07-13.
What interventions are being tested in trial NCT02730871?
The interventions under investigation include: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension (DRUG), Brinzolamide/brimonidine vehicle (DRUG), Travoprost 0.004%/timolol 0.5% solution (DRUG).
Who is sponsoring clinical trial NCT02730871?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02730871's enrollment target sits among peer trials
173 481st of 2000 higher than 1,520 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI